Kazia Therapeutics Launches Groundbreaking Clinical Trial Combining Paxalisib and Immunotherapy for Advanced Breast Cancer

Kazia Therapeutics Limited (NASDAQ: KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch...

January 31, 2025 | Friday | News
Amgen Announces European Commission Approval of BLINCYTO® for Frontline Treatment of B-ALL

Amgen (NASDAQ:AMGN) announced that the European Commission (EC) has approved BLINCYTO® (blinatumomab) monotherapy as part of consolidation therapy...

January 31, 2025 | Friday | News
Advanced Aesthetic Technologies Receives Approval for Algeness® Dermal Filler in China

Advanced Aesthetic Technologies, Inc. ("AAT") announced  that their partner in China has obtained approval to market their unique dermal fil...

January 29, 2025 | Wednesday | News
GSK's Depemokimab Accepted for EMA Review in Asthma and Chronic Rhinosinusitis with Nasal Polyps

GSK plc (LSE/NYSE: GSK) announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemok...

January 29, 2025 | Wednesday | News
Roche Announces Positive Overall Survival Results for Itovebi™ in Advanced Breast Cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive topline results from the overall survival (OS) analysis of the phase III INAVO120 study investigating...

January 29, 2025 | Wednesday | News
Pfizer to Present Groundbreaking Genitourinary Cancer Research at ASCO GU 2025

Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitour...

January 29, 2025 | Wednesday | News
European Commission Approves LAZCLUZE® (lazertinib) and RYBREVANT® (amivantamab) for First-Line Treatment of EGFR-Mutant Advanced NSCLC

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission (EC) has granted marketing authorization (MA) to LA...

January 28, 2025 | Tuesday | News
Roche Reports Positive Two-Year Results from EMBARK Trial for Elevidys™, First Gene Therapy for Duchenne Muscular Dystrophy

Roche announced  positive topline results from year two of the EMBARK trial, a global, randomised, double-blind phase III study of Elevidys™ (de...

January 28, 2025 | Tuesday | News
Merck and Eisai Announce Promising Interim Results from LEAP-015 Trial of KEYTRUDA® and LENVIMA® in HER2-Negative Gastroesophageal Adenocarcinoma

 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai announced results from the Phase 3 LEAP-015 trial evaluating KEYTR...

January 27, 2025 | Monday | News
Pfizer's BRAFTOVI® Combination Therapy Demonstrates Significant Clinical Benefit in Metastatic Colorectal Cancer with BRAF V600E Mutation

 Pfizer Inc. (NYSE: PFE) announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination ...

January 27, 2025 | Monday | News
CG Pharmaceuticals Presents Promising Results for Ivaltinostat in Metastatic Pancreatic Cancer at ASCO GI Symposium

CG Pharmaceuticals (CG Pharma), a clinical biopharmaceutical company located in the San Francisco Bay Area, was established as an independent entity i...

January 24, 2025 | Friday | News
AstraZeneca Announces C$820 Million Investment in Ontario, Creating Over 700 High-Skilled Jobs

AstraZeneca, a global pharmaceutical company focused on developing life changing medicines,  announced a C$820 million (US$570m) investment in Canada,...

January 24, 2025 | Friday | News
Disc Medicine Announces Upsized $225.5 Million Public Offering of Common Stock and Pre-Funded Warrants

Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...

January 23, 2025 | Thursday | News
GC Cell Hosts First Thought Leadership Symposium in Jakarta, Showcasing Immuncell-LC’s Potential in Cancer Treatment

GC Cell, a leading cell and gene therapy company, announced the successful completion of its first thought leadership symposium in Jakarta, Indonesia....

January 23, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close